ONCOTELIC THERAPEUTCS (OTLC) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OTLC SEC filings page.
This page shows ONCOTELIC THERAPEUTCS INC (OTLC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025’s reported profit came from outside day-to-day operations, while operating losses and negative cash flow continued.
FY2025 combined net income of$249.3M with operating income of-$3.2M and operating cash flow of-$1.4M : the accounting gain did not represent cash generated by the business. That gap makes the year’s earnings quality unusually dependent on non-operating items rather than recurring activity.
The balance sheet changed dramatically in FY2025: assets increased
Short-term liquidity remains structurally tight despite lower overall leverage: current assets were only
Financial Health Signals
ONCOTELIC THERAPEUTCS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
ONCOTELIC THERAPEUTCS INC passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
For every $1 of reported earnings, ONCOTELIC THERAPEUTCS INC used $0.01 of operating cash (-$1.4M OCF vs $249.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
ONCOTELIC THERAPEUTCS INC generated $250K in revenue in Q2 2026.
ONCOTELIC THERAPEUTCS INC reported $388K in net income in Q2 2026. This represents an increase of 39.7% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
ONCOTELIC THERAPEUTCS INC earned $0.00 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Cash & Balance Sheet
ONCOTELIC THERAPEUTCS INC held $186K in cash against $1.9M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
ONCOTELIC THERAPEUTCS INC's quarterly ROE was 0.1% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 3.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.0 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
ONCOTELIC THERAPEUTCS INC invested $345 in research and development in Q2 2026. This represents an increase of 16.2% from the same quarter a year earlier. Against the prior quarter it is down 56.6%.
Not reported for Q2 2026.
Not reported for Q2 2026.
OTLC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $250K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $345+16.2% | $795+167.7% | N/A | N/A | $297+17.9% | $297-38.1% | N/A | $480-97.7% |
| SG&A Expenses | $1.1M+1564.7% | $1.9M+1737.8% | N/A | $491K+511.1% | $66K-31.8% | $101K-39.5% | N/A | $80K+134.0% |
| Operating Income | -$844Kn/m | -$1.9Mn/m | N/A | -$491Kn/m | -$66Kn/m | -$101Kn/m | N/A | -$3.3M-22760.3% |
| Interest Expense | $318K+53.2% | N/A | N/A | N/A | $208K+2373.6% | N/A | N/A | $8K-95.5% |
| Net Income | $388K+39.7% | -$2.2Mn/m | N/A | -$1.0Mn/m | $278Kn/m | -$299Kn/m | N/A | -$3.3M-2965.8% |
| EPS (Basic) | $0.00n/m | $0.00n/m | $0.59n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | -$0.01n/m |
| EPS (Diluted) | $0.00n/m | $0.00n/m | N/A | N/A | $0.00n/m | $0.00n/m | N/A | -$0.01n/m |
| Diluted Shares (Avg) | 468M+3.3% | 444M+8.9% | N/A | N/A | 453M+12.8% | 407M+2.0% | N/A | 407M+2.4% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA, Income Tax.
OTLC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $394.8M+1379.5% | $394.0M+1377.2% | $393.1M+1373.5% | $28.2M+5.1% | $26.7M-10.9% | $26.7M-11.0% | $26.7M-11.1% | $26.8M-11.0% |
| Current Assets | $1.5M+961.6% | $2.1M+1552.1% | $1.2M+792.8% | $1.6M+574.8% | $138K-28.3% | $125K-45.9% | $134K-50.6% | $239K-34.6% |
| Cash & Equivalents | $186K+111.3% | $64K-19.7% | $89K+3.2% | $409K+174.5% | $88K+21.9% | $79K-58.1% | $86K-49.5% | $149K-44.4% |
| Accounts Receivable | $2K-89.2% | $2K-89.2% | $51K+170.5% | $4K-79.0% | $19K0.0% | $19K0.0% | $19K0.0% | $19K0.0% |
| Goodwill | $2.8M0.0% | $2.8M0.0% | $2.8M0.0% | $2.8M0.0% | $2.8M-53.4% | $2.8M-53.4% | $2.8M-53.4% | $2.8M-53.4% |
| Total Liabilities | $131.3M+580.8% | $131.7M+576.1% | $131.4M+584.2% | $20.1M+7.7% | $19.3M+4.6% | $19.5M+4.1% | $19.2M+4.3% | $18.7M+6.3% |
| Current Liabilities | $17.9M-7.2% | $18.4M-5.5% | $18.1M-5.5% | $20.1M+22.8% | $19.3M+19.0% | $19.5M+18.0% | $19.2M+16.3% | $16.4M-4.4% |
| Non-Current Liabilities | $113.4Mn/m | $113.3Mn/m | $113.2Mn/m | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $2.3M+426.4% |
| Long-Term Debt | $1.9M | $1.8M | $1.7M | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $264.6M+3087.1% | $263.3M+3181.6% | $262.8M+3084.3% | $9.1M+2.2% | $8.3M-31.7% | $8.0M-32.2% | $8.3M-32.0% | $8.9M-29.5% |
| Retained Earnings | $209.4Mn/m | $209.0Mn/m | $211.2Mn/m | -$39.1Mn/m | -$38.1Mn/m | -$38.3Mn/m | -$38.0Mn/m | -$37.4Mn/m |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments.
OTLC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$92Kn/m | -$342Kn/m | -$783Kn/m | -$307Kn/m | -$126Kn/m | -$167Kn/m | -$104Kn/m | -$143Kn/m |
| Stock-Based Compensation | N/A | $1.6Mn/m | N/A | N/A | N/A | $0n/m | N/A | N/A |
| Financing Cash Flow | $215K+59.0% | $317K+98.1% | $463K+1029.0% | $628K+185.5% | $135K-6.9% | $160K-36.0% | $41K-85.1% | $220K-34.3% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
OTLC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -337.4% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | 155.3% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | 0.1%-3.2pp | -0.8%+2.9pp | N/A | -11.6%+25.8pp | 3.4%+5.1pp | -3.7%-0.3pp | N/A | -37.3%-38.3pp |
| Return on Assets | 0.1%-0.9pp | -0.6%+0.6pp | N/A | -3.7%+8.6pp | 1.0%+1.7pp | -1.1%+0.2pp | N/A | -12.3%-12.7pp |
| Current Ratio | 0.08+0.1x | 0.11+0.1x | 0.07+0.1x | 0.08+0.1x | 0.010.0x | 0.010.0x | 0.010.0x | 0.010.0x |
| Debt-to-Equity | 0.01 | 0.01 | 0.01 | N/A | N/A | N/A | N/A | N/A |
| Liabilities-to-Equity | 0.50-1.8x | 0.50-1.9x | 0.50-1.8x | 2.22+0.1x | 2.32+0.8x | 2.43+0.8x | 2.33+0.8x | 2.11+0.7x |
| Asset Turnover | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: The current ratio is below 1.0 (0.07), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| ONCOTELIC THERAPEUTCS INC OTLC | FY2025 | N/A | $249.3M | N/A | $8.6M | — |
| ACCUSTEM SCIENCES INC ACUT | FY2025 | N/A | -$1.8M | N/A | $2.4M | — |
| HARVARD APPRATS REG TCH HRGN | FY2025 | $704K | -$6.9M | N/A | $39.8M | — |
Where ONCOTELIC THERAPEUTCS INC Ranks
Frequently Asked Questions
Is ONCOTELIC THERAPEUTCS INC profitable?
Yes, ONCOTELIC THERAPEUTCS INC (OTLC) reported a net income of $249.3M in fiscal year 2025.
How much debt does ONCOTELIC THERAPEUTCS INC have?
As of fiscal year 2025, ONCOTELIC THERAPEUTCS INC (OTLC) had $89K in cash and equivalents against $1.7M in long-term debt.
What is ONCOTELIC THERAPEUTCS INC's return on equity (ROE)?
ONCOTELIC THERAPEUTCS INC (OTLC) has a return on equity of 94.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is ONCOTELIC THERAPEUTCS INC's operating cash flow?
ONCOTELIC THERAPEUTCS INC (OTLC) recorded an outflow of $1.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are ONCOTELIC THERAPEUTCS INC's total assets?
ONCOTELIC THERAPEUTCS INC (OTLC) had $393.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does ONCOTELIC THERAPEUTCS INC spend on research and development?
ONCOTELIC THERAPEUTCS INC (OTLC) invested $4K in research and development during fiscal year 2025.
What is ONCOTELIC THERAPEUTCS INC's current ratio?
ONCOTELIC THERAPEUTCS INC (OTLC) had a current ratio of 0.07 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is ONCOTELIC THERAPEUTCS INC's debt-to-equity ratio?
ONCOTELIC THERAPEUTCS INC (OTLC) had a debt-to-equity ratio of 0.01 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is ONCOTELIC THERAPEUTCS INC's liabilities-to-equity ratio?
ONCOTELIC THERAPEUTCS INC (OTLC) had a liabilities-to-equity ratio of 0.50 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is ONCOTELIC THERAPEUTCS INC's return on assets (ROA)?
ONCOTELIC THERAPEUTCS INC (OTLC) had a return on assets of 63.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is ONCOTELIC THERAPEUTCS INC's P/E ratio?
ONCOTELIC THERAPEUTCS INC (OTLC) trades at 0.0x earnings, its market capitalization divided by $249.3M net income, FY2025. The market capitalization is $8.6M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ONCOTELIC THERAPEUTCS INC's price-to-sales ratio?
ONCOTELIC THERAPEUTCS INC (OTLC) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $8.6M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ONCOTELIC THERAPEUTCS INC's Piotroski F-Score?
ONCOTELIC THERAPEUTCS INC (OTLC) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ONCOTELIC THERAPEUTCS INC's earnings high quality?
For every $1 of reported earnings, ONCOTELIC THERAPEUTCS INC (OTLC) used $0.01 of operating cash (-$1.4M OCF vs $249.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.